Compare Ginkgo Bioworks Holdings Inc (DNA) vs IAC/Interactivecorp (PPLI) Price & Performance

Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.

The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.

PPLI trades at $40.59, down 1.7% in the past 24 hours, with a bullish technical signal from moving averages. The stock shows mixed fundamentals: revenue declined to $2.39B in 2025 with a net loss of $104.03M, but valuation ratios appear attractive with a P/E of 6.87 and P/B of 0.59. Recent news highlights potential M&A activity, as MGM Resorts is reportedly considering a bid for PPLI, following PPLI's withdrawal of its own offer to buy MGM.

The outlook is cautiously optimistic, supported by strong analyst consensus (71.4% buy ratings) and potential upside from strategic deals. Key risks include inconsistent profitability, high debt levels, and execution challenges in a competitive media landscape. Earnings volatility remains a concern, but the low valuation and M&A speculation provide catalysts for investor interest.